TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02083432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 session of CBT performed by specially trained dentists
Description: A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5 session of CBT performed by specially trained dentists
Description: A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
Study: NCT01756950

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered as a single 2-hour intravenous infusion
Study: NCT05596305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational psychiatry intervention
Description: educational anti-stigma intervention related to psychiatric illness composed of a lecture, video, role models play, and open discussion
Study: NCT02107209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Lung volume reduction
Description: Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic Lung volume reduction
Description: Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
Study: NCT03076970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasmiditan 200 mg
Description: drug including single placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasmiditan 200 mg
Description: drug including single placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: drug including single placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: drug including single placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Description: single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo
Description: single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
Study: NCT04581525

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study: NCT01990846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Flufirvitide-3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Flufirvitide-3
Study: NCT00785408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2307
Description: subcutaneous, twice daily, low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous, twice daily, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2307
Description: subcutaneous, twice daily, middle dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous, twice daily, middle dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2307
Description: subcutaneous, twice daily, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous, twice daily, high dose
Study: NCT01345630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc tablet 150 mg once daily for 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir
Description: Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 800/100 mg
Description: darunavir/ritonavir 800/100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for emtricitabine/tenofovir
Description: placebo for emtricitabine/tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for maraviroc
Description: placebo for maraviroc
Study: NCT03940599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: step counter
Description: Fitbit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: step counter
Description: Fitbit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: weight scale
Description: BodyTrace weight scale

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: weight scale
Description: BodyTrace weight scale

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: step counter with screen covered
Description: Fitbit with screen covered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: step counter with screen covered
Description: Fitbit with screen covered
Study: NCT03664479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study: NCT05399745

Intervention type: OTHER
Intervention: Neurocognitive monitoring
Description: Neurocognitive tests and MRI of the brain

Intervention type: OTHER
Intervention: Neurocognitive monitoring
Description: Neurocognitive tests and MRI of the brain

Intervention type: OTHER
Intervention: Neurocognitive monitoring
Description: Neurocognitive tests and MRI of the brain
Study: NCT04051268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT Typhoid Conjugate Vaccine
Description: 1 dose of Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT Typhoid Conjugate Vaccine
Description: 1 dose of Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT Typhoid Conjugate Vaccine
Description: 1 dose of Investigational Product

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PQed Typhoid Conjugate Vaccine
Description: 1 dose of Active Comparator

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide Vaccine
Description: 1 dose of Active Comparator
Study: NCT03568370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olive oil
Description: Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
Study: NCT00275028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study: NCT00669578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: CC-4047: taken orally each day in a 28 day cycle.
Study: NCT03734289

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Coaching
Description: Online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Coaching
Description: Online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
Study: NCT02921932

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure, Resource 2.0 and Glucerna
Description: Preoperative nutritional supplement for undernourished patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training, Memory Card Game
Description: Preoperative memory card game
Study: NCT03948750

Intervention type: PROCEDURE
Intervention: Aqueous humour sampling
Description: Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting

Intervention type: PROCEDURE
Intervention: Aqueous humour sampling
Description: Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
Study: NCT00915031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroCool
Description: Hypothermia Endorectal Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroCool
Description: Hypothermia Endorectal Device
Study: NCT01236079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted referral & IVR
Description: includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
Study: NCT02119260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 solution
Description: Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 solution
Description: Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 solution
Description: Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 suspension
Description: Aqueous suspension of GSK2798745 (\>=0.5 mg)
Study: NCT02921932

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc
Description: Inspiratory muscle trainer protocol for strengthening respiratory muscles
Study: NCT01561326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-affective barriers counseling
Description: Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-affective barriers counseling via brochure
Description: Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
Study: NCT02119260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 suspension
Description: Aqueous suspension of GSK2798745 (\>=0.5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 suspension
Description: Aqueous suspension of GSK2798745 (\>=0.5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 capsule
Description: White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)
Study: NCT02847091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Oral administration, 50mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
Study: NCT02339532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC100
Description: 3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: CARBOPLATIN AUC 6 IV q3w
Study: NCT04553471

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Treatment will take approximately 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
Study: NCT02230020

Intervention type: DEVICE
Intervention: Nasal High Flow
Study: NCT01661244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568 repeat dose
Description: Safety and tolerability of escalating repeat doses in normal human volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568 matching placebo repeat dose
Description: Safety and tolerability of escalating repeat doses in normal human volunteers.
Study: NCT04606394

Intervention type: DRUG
Group type: OTHER
Intervention: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Description: Administration of Trelegy in all patients

Intervention type: DRUG
Group type: OTHER
Intervention: Ventolin 90Mcg/Actuation Inhalation Aerosol
Description: 2 hours after the administration of Trelegy, administer Ventolin in all patients
Study: NCT03574272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Transfer Monitoring System
Description: The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
Study: NCT04271514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT193
Description: Antagonist of the CCR4 chemokine receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT193
Description: Antagonist of the CCR4 chemokine receptor
Study: NCT02494245

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STARFISH
Description: The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
Study: NCT00996554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double layer-suture
Description: Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
Study: NCT05322889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan tablets
Description: 12 weeks treatment
Study: NCT02119260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 capsule
Description: White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 capsule
Description: White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 capsule
Description: White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: Clear, colourless solution of aqueous citrate buffer with 4% captisol
Study: NCT00996554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-layer suture
Description: Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
Study: NCT02119260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: Clear, colourless solution of aqueous citrate buffer with 4% captisol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suspension
Description: Visually matching aqueous suspension of hypromellose acetate succinate powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suspension
Description: Visually matching aqueous suspension of hypromellose acetate succinate powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching white opaque placebo blend filled capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching white opaque placebo blend filled capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching white opaque placebo blend filled capsule
Study: NCT01615874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF/F Metered Dose Inhaler (MDI) 25/5 mcg
Description: MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF/F MDI 50/5 mcg
Description: MF/F MDI 50/5 mcg, 2 inhalations BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF/F MDI 100/5 mcg
Description: MF/F MDI 100/5 mcg, 2 inhalations BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP hydrofluoroalkane (HFA) 80 mcg
Description: BDP HFA 80 mcg, 2 inhalations BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast tablets 5 mg (4 mg for children 5 years of age)
Description: Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue medication: short-acting beta-2 agonist (SABA) MDI
Description: albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication: short-acting beta-2 agonist (SABA) MDI
Description: albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication: short-acting beta-2 agonist (SABA) MDI
Description: albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication: short-acting beta-2 agonist (SABA) MDI
Description: albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue medication: short-acting beta-2 agonist (SABA) MDI
Description: albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue medication: Prednisone/Prednisolone
Description: Prednisone/Prednisolone for rescue medication, taken as directed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication: Prednisone/Prednisolone
Description: Prednisone/Prednisolone for rescue medication, taken as directed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication: Prednisone/Prednisolone
Description: Prednisone/Prednisolone for rescue medication, taken as directed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication: Prednisone/Prednisolone
Description: Prednisone/Prednisolone for rescue medication, taken as directed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue medication: Prednisone/Prednisolone
Description: Prednisone/Prednisolone for rescue medication, taken as directed
Study: NCT03578003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning Bright Light Therapy
Description: 60 minutes of bright light therapy (10,000 lux) received within 90 minutes of waking
Study: NCT01928420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: NIC5-15
Description: A natural product, found in many foods and plants with mild insulin sensitizing effects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with Alzheimer's Disease placebo comparator